A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chloroquine should be monitored for hypoglycaemia, even after recovery.
All Keywords
【저자키워드】 Type 1 diabetes, Chloroquine, Remission, Hypoglycaemia,
【저자키워드】 Type 1 diabetes, Chloroquine, Remission, Hypoglycaemia,